B. Riley Securities Initiates Coverage On Lyell Immunopharma with Buy Rating, Announces Price Target of $44
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsInitiationPrice Target
B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.
B. Riley Securities analyst Yuan Zhi initiates coverage on Lyell Immunopharma (NASDAQ:LYEL) with a Buy rating and announces Price Target of $44.